STOCK TITAN

[8-K] Global Medical REIT Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Arteris, Inc. (AIP) – Form 144 filing

An affiliated insider has filed to sell up to 50,000 common shares on or after 05 Aug 2025 through Morgan Stanley Smith Barney. The notice values the block at about $472,500, implying a reference price of roughly $9.45 per share. With 41.98 million shares outstanding, the proposed sale represents only ~0.12 % of outstanding stock, suggesting minimal direct market impact.

The shares were originally acquired on 05 Nov 2013 via a private transaction with the issuer. Recent Rule 10b5-1 activity shows the same filer sold 40,254 shares between 27 Jun and 03 Jul 2025 for aggregate proceeds of about $384 k. A Form 144 is a notice of intent—execution is not guaranteed—but it extends a pattern of insider monetisation. While the size is modest, continued sales can create a slight supply overhang; conversely, use of a pre-arranged trading plan points to routine diversification rather than a negative signal on fundamentals.

Arteris, Inc. (AIP) – Presentazione del Modulo 144

Un insider affiliato ha presentato la richiesta di vendita di fino a 50.000 azioni ordinarie a partire dal 05 agosto 2025 tramite Morgan Stanley Smith Barney. La notifica valuta il blocco a circa 472.500 $, con un prezzo di riferimento stimato intorno a 9,45 $ per azione. Con 41,98 milioni di azioni in circolazione, la vendita proposta rappresenta solo circa il 0,12% del capitale sociale, suggerendo un impatto diretto minimo sul mercato.

Le azioni sono state originariamente acquisite il 05 novembre 2013 tramite una transazione privata con l'emittente. Recenti operazioni ai sensi della Regola 10b5-1 mostrano che lo stesso soggetto ha venduto 40.254 azioni tra il 27 giugno e il 03 luglio 2025 per un ricavo complessivo di circa 384.000 $. Il Modulo 144 è una comunicazione di intenti — l’esecuzione non è garantita — ma conferma una tendenza di monetizzazione da parte degli insider. Sebbene la dimensione sia modesta, vendite continue possono creare un leggero eccesso di offerta; d'altra parte, l'utilizzo di un piano di trading predefinito indica una diversificazione ordinaria piuttosto che un segnale negativo sui fondamentali.

Arteris, Inc. (AIP) – Presentación del Formulario 144

Un insider afiliado ha presentado la intención de vender hasta 50,000 acciones comunes a partir del 05 de agosto de 2025 a través de Morgan Stanley Smith Barney. El aviso valora el bloque en aproximadamente $472,500, lo que implica un precio de referencia de alrededor de $9.45 por acción. Con 41.98 millones de acciones en circulación, la venta propuesta representa solo aproximadamente el 0.12 % del capital social, lo que sugiere un impacto directo mínimo en el mercado.

Las acciones fueron adquiridas originalmente el 05 de noviembre de 2013 mediante una transacción privada con el emisor. La actividad reciente bajo la Regla 10b5-1 muestra que el mismo declarante vendió 40,254 acciones entre el 27 de junio y el 03 de julio de 2025 por ingresos totales de aproximadamente $384,000. Un Formulario 144 es un aviso de intención — la ejecución no está garantizada — pero extiende un patrón de monetización por parte de los insiders. Aunque el tamaño es modesto, las ventas continuas pueden crear un ligero exceso de oferta; por otro lado, el uso de un plan de trading preestablecido apunta a una diversificación rutinaria más que a una señal negativa sobre los fundamentos.

Arteris, Inc. (AIP) – Form 144 제출

관련 내부자가 2025년 8월 5일 이후에 Morgan Stanley Smith Barney를 통해 최대 50,000주 보통주를 매도하기 위해 신고했습니다. 공시에서는 해당 주식 블록의 가치를 약 $472,500로 평가하며, 주당 약 $9.45의 기준 가격을 시사합니다. 총 41.98백만 주가 발행된 가운데, 이번 매도는 전체 주식의 약 0.12%에 불과해 시장에 미치는 직접적인 영향은 미미할 것으로 보입니다.

이 주식은 2013년 11월 5일 발행사와의 비공개 거래를 통해 처음 취득되었습니다. 최근 Rule 10b5-1에 따른 거래 내역에 따르면, 동일한 신고자가 2025년 6월 27일부터 7월 3일까지 총 40,254주를 매도하여 약 $384,000의 수익을 올렸습니다. Form 144는 의도 통지서로, 실제 매도 실행이 보장되는 것은 아니지만 내부자의 자산 현금화 패턴을 보여줍니다. 규모는 크지 않지만 지속적인 매도는 약간의 공급 과잉을 초래할 수 있으며, 반면 미리 정해진 거래 계획을 사용하는 것은 기본적인 펀더멘털에 대한 부정적 신호보다는 일상적인 다각화의 일환임을 나타냅니다.

Arteris, Inc. (AIP) – Dépôt du formulaire 144

Un initié affilié a déposé une intention de vendre jusqu'à 50 000 actions ordinaires à partir du 5 août 2025 via Morgan Stanley Smith Barney. L'avis valorise le lot à environ 472 500 $, ce qui implique un prix de référence d'environ 9,45 $ par action. Avec 41,98 millions d'actions en circulation, la vente proposée représente seulement environ 0,12 % du capital en circulation, suggérant un impact direct minimal sur le marché.

Les actions ont été initialement acquises le 5 novembre 2013 lors d'une transaction privée avec l'émetteur. Les récentes opérations selon la règle 10b5-1 montrent que le même déclarant a vendu 40 254 actions entre le 27 juin et le 3 juillet 2025 pour un produit total d'environ 384 000 $. Un formulaire 144 est un avis d'intention — son exécution n'est pas garantie — mais il confirme une tendance de monétisation des initiés. Bien que le volume soit modeste, des ventes continues peuvent créer un léger excédent d'offre ; en revanche, l'utilisation d'un plan de trading préétabli indique une diversification de routine plutôt qu'un signal négatif sur les fondamentaux.

Arteris, Inc. (AIP) – Meldung Formular 144

Ein verbundener Insider hat die Absicht gemeldet, bis zu 50.000 Stammaktien ab dem 05. August 2025 über Morgan Stanley Smith Barney zu verkaufen. Die Meldung bewertet das Paket auf etwa 472.500 $, was auf einen Referenzpreis von etwa 9,45 $ pro Aktie hindeutet. Bei 41,98 Millionen ausstehenden Aktien entspricht der geplante Verkauf nur etwa 0,12 % des ausstehenden Aktienkapitals, was auf eine minimale direkte Marktwirkung schließen lässt.

Die Aktien wurden ursprünglich am 05. November 2013 in einer Privattransaktion mit dem Emittenten erworben. Jüngste Aktivitäten gemäß Regel 10b5-1 zeigen, dass derselbe Melder zwischen dem 27. Juni und 03. Juli 2025 40.254 Aktien verkaufte und dabei Erlöse von rund 384.000 $ erzielte. Ein Formular 144 ist eine Absichtserklärung – die Ausführung ist nicht garantiert – bestätigt jedoch ein Muster der Monetarisierung durch Insider. Obwohl die Größe moderat ist, können fortgesetzte Verkäufe einen leichten Angebotsüberhang erzeugen; andererseits deutet die Nutzung eines vorab vereinbarten Handelsplans auf routinemäßige Diversifikation und nicht auf ein negatives Signal für die Fundamentaldaten hin.

Positive
  • Use of a Rule 10b5-1 trading plan enhances transparency and reduces perception of opportunistic insider trading.
  • Sale size is only ~0.12 % of shares outstanding, indicating limited direct market pressure.
Negative
  • Continued insider selling—40 k shares in prior three months plus 50 k planned—may create a modest supply overhang and raise sentiment concerns.

Insights

TL;DR: Small insider sale (~0.12% OS); routine diversification, limited price impact.

The proposed 50 k-share sale is immaterial relative to Arteris’ 41.98 m shares outstanding and is routed through a Rule 10b5-1 plan, framing it as planned liquidity rather than reactive selling. Combined with prior 40 k shares sold over the past quarter, insider disposition totals ~0.22 % of float—still modest. Investors typically discount such volumes, so I view the filing as neutral; the chief takeaway is continued transparency rather than a material shift in insider sentiment.

TL;DR: Filing signals governance compliance; minimal ownership change risk.

Management’s adherence to Rule 144 and 10b5-1 underscores solid compliance practices. The staggered, pre-scheduled sales help mitigate potential claims of trading on non-public information. Because the quantity is small and disclosed ahead of time, I do not view it as a governance red flag. The transaction neither alters control structures nor suggests strategic shifts. Overall governance impact: neutral.

Arteris, Inc. (AIP) – Presentazione del Modulo 144

Un insider affiliato ha presentato la richiesta di vendita di fino a 50.000 azioni ordinarie a partire dal 05 agosto 2025 tramite Morgan Stanley Smith Barney. La notifica valuta il blocco a circa 472.500 $, con un prezzo di riferimento stimato intorno a 9,45 $ per azione. Con 41,98 milioni di azioni in circolazione, la vendita proposta rappresenta solo circa il 0,12% del capitale sociale, suggerendo un impatto diretto minimo sul mercato.

Le azioni sono state originariamente acquisite il 05 novembre 2013 tramite una transazione privata con l'emittente. Recenti operazioni ai sensi della Regola 10b5-1 mostrano che lo stesso soggetto ha venduto 40.254 azioni tra il 27 giugno e il 03 luglio 2025 per un ricavo complessivo di circa 384.000 $. Il Modulo 144 è una comunicazione di intenti — l’esecuzione non è garantita — ma conferma una tendenza di monetizzazione da parte degli insider. Sebbene la dimensione sia modesta, vendite continue possono creare un leggero eccesso di offerta; d'altra parte, l'utilizzo di un piano di trading predefinito indica una diversificazione ordinaria piuttosto che un segnale negativo sui fondamentali.

Arteris, Inc. (AIP) – Presentación del Formulario 144

Un insider afiliado ha presentado la intención de vender hasta 50,000 acciones comunes a partir del 05 de agosto de 2025 a través de Morgan Stanley Smith Barney. El aviso valora el bloque en aproximadamente $472,500, lo que implica un precio de referencia de alrededor de $9.45 por acción. Con 41.98 millones de acciones en circulación, la venta propuesta representa solo aproximadamente el 0.12 % del capital social, lo que sugiere un impacto directo mínimo en el mercado.

Las acciones fueron adquiridas originalmente el 05 de noviembre de 2013 mediante una transacción privada con el emisor. La actividad reciente bajo la Regla 10b5-1 muestra que el mismo declarante vendió 40,254 acciones entre el 27 de junio y el 03 de julio de 2025 por ingresos totales de aproximadamente $384,000. Un Formulario 144 es un aviso de intención — la ejecución no está garantizada — pero extiende un patrón de monetización por parte de los insiders. Aunque el tamaño es modesto, las ventas continuas pueden crear un ligero exceso de oferta; por otro lado, el uso de un plan de trading preestablecido apunta a una diversificación rutinaria más que a una señal negativa sobre los fundamentos.

Arteris, Inc. (AIP) – Form 144 제출

관련 내부자가 2025년 8월 5일 이후에 Morgan Stanley Smith Barney를 통해 최대 50,000주 보통주를 매도하기 위해 신고했습니다. 공시에서는 해당 주식 블록의 가치를 약 $472,500로 평가하며, 주당 약 $9.45의 기준 가격을 시사합니다. 총 41.98백만 주가 발행된 가운데, 이번 매도는 전체 주식의 약 0.12%에 불과해 시장에 미치는 직접적인 영향은 미미할 것으로 보입니다.

이 주식은 2013년 11월 5일 발행사와의 비공개 거래를 통해 처음 취득되었습니다. 최근 Rule 10b5-1에 따른 거래 내역에 따르면, 동일한 신고자가 2025년 6월 27일부터 7월 3일까지 총 40,254주를 매도하여 약 $384,000의 수익을 올렸습니다. Form 144는 의도 통지서로, 실제 매도 실행이 보장되는 것은 아니지만 내부자의 자산 현금화 패턴을 보여줍니다. 규모는 크지 않지만 지속적인 매도는 약간의 공급 과잉을 초래할 수 있으며, 반면 미리 정해진 거래 계획을 사용하는 것은 기본적인 펀더멘털에 대한 부정적 신호보다는 일상적인 다각화의 일환임을 나타냅니다.

Arteris, Inc. (AIP) – Dépôt du formulaire 144

Un initié affilié a déposé une intention de vendre jusqu'à 50 000 actions ordinaires à partir du 5 août 2025 via Morgan Stanley Smith Barney. L'avis valorise le lot à environ 472 500 $, ce qui implique un prix de référence d'environ 9,45 $ par action. Avec 41,98 millions d'actions en circulation, la vente proposée représente seulement environ 0,12 % du capital en circulation, suggérant un impact direct minimal sur le marché.

Les actions ont été initialement acquises le 5 novembre 2013 lors d'une transaction privée avec l'émetteur. Les récentes opérations selon la règle 10b5-1 montrent que le même déclarant a vendu 40 254 actions entre le 27 juin et le 3 juillet 2025 pour un produit total d'environ 384 000 $. Un formulaire 144 est un avis d'intention — son exécution n'est pas garantie — mais il confirme une tendance de monétisation des initiés. Bien que le volume soit modeste, des ventes continues peuvent créer un léger excédent d'offre ; en revanche, l'utilisation d'un plan de trading préétabli indique une diversification de routine plutôt qu'un signal négatif sur les fondamentaux.

Arteris, Inc. (AIP) – Meldung Formular 144

Ein verbundener Insider hat die Absicht gemeldet, bis zu 50.000 Stammaktien ab dem 05. August 2025 über Morgan Stanley Smith Barney zu verkaufen. Die Meldung bewertet das Paket auf etwa 472.500 $, was auf einen Referenzpreis von etwa 9,45 $ pro Aktie hindeutet. Bei 41,98 Millionen ausstehenden Aktien entspricht der geplante Verkauf nur etwa 0,12 % des ausstehenden Aktienkapitals, was auf eine minimale direkte Marktwirkung schließen lässt.

Die Aktien wurden ursprünglich am 05. November 2013 in einer Privattransaktion mit dem Emittenten erworben. Jüngste Aktivitäten gemäß Regel 10b5-1 zeigen, dass derselbe Melder zwischen dem 27. Juni und 03. Juli 2025 40.254 Aktien verkaufte und dabei Erlöse von rund 384.000 $ erzielte. Ein Formular 144 ist eine Absichtserklärung – die Ausführung ist nicht garantiert – bestätigt jedoch ein Muster der Monetarisierung durch Insider. Obwohl die Größe moderat ist, können fortgesetzte Verkäufe einen leichten Angebotsüberhang erzeugen; andererseits deutet die Nutzung eines vorab vereinbarten Handelsplans auf routinemäßige Diversifikation und nicht auf ein negatives Signal für die Fundamentaldaten hin.

false 0001533615 0001533615 2025-08-05 2025-08-05 0001533615 us-gaap:CommonStockMember 2025-08-05 2025-08-05 0001533615 us-gaap:SeriesAPreferredStockMember 2025-08-05 2025-08-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE 

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 5, 2025 (August 5, 2025)

 

Global Medical REIT Inc.

(Exact name of registrant as specified in its charter)

 

Maryland 001-37815 46-4757266

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

7373 Wisconsin Avenue, Suite 800

Bethesda, MD

20814

(Address of Principal Executive Offices)

(Zip Code)

 

(202) 524-6851

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbols:   Name of each exchange on which registered:
Common Stock, par value $0.001 per share   GMRE   NYSE
Series A Preferred Stock, par value $0.001 per share   GMRE PrA   NYSE

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 5, 2025, Global Medical REIT Inc. (the “Company”) announced its financial position as of June 30, 2025 and operating results for the three and six months ended June 30, 2025 and other related information (the “Earnings Release”). The Company also posted its Second Quarter 2025 Earnings Supplemental (the “Supplemental”) to the Company’s website at www.globalmedicalreit.com. The Earnings Release and Supplemental are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

 

The information included in this Item 2.02 of this Current Report on Form 8-K, including the Earnings Release and Supplemental, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. 

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  Exhibits

 

Exhibit
No.
  Description
99.1*   Second Quarter 2025 Earnings Release.
99.2*   Second Quarter 2025 Earnings Supplemental.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*Furnished herewith

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Global Medical REIT Inc.
     
  By: /s/ Jamie A. Barber
    Jamie A. Barber
    Secretary and General Counsel

  

Date: August 5, 2025

 

 

FAQ

How many Arteris (AIP) shares are proposed for sale in this Form 144?

The filing covers 50,000 common shares.

What is the estimated dollar value of the planned sale?

The notice values the block at approximately $472,500.

What percentage of Arteris’ outstanding shares does 50,000 represent?

Roughly 0.12 % of the 41.98 million shares outstanding.

When is the earliest sale date under the Form 144?

On or after 05 Aug 2025.

Which broker will execute the transaction?

Morgan Stanley Smith Barney LLC is listed as the executing broker.

How many shares has the insider already sold in the last three months?

A total of 40,254 shares were sold between 27 Jun and 03 Jul 2025.
Global Medical

NYSE:GMRE

GMRE Rankings

GMRE Latest News

GMRE Latest SEC Filings

GMRE Stock Data

451.43M
62.94M
5.88%
70.18%
3.96%
REIT - Healthcare Facilities
Real Estate Investment Trusts
Link
United States
BETHESDA